• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.

作者信息

Mina Roberto, Joseph Nisha S, Gay Francesca, Kastritis Efstathios, Petrucci Maria Teresa, Kaufman Jonathan L, Montefusco Vittorio, Gavriatopoulou Maria, Patriarca Francesca, Omedé Paola, Boise Lawrence H, Roussou Maria, Giuliani Nicola, Oliva Stefania, Offidani Massimo, Belotti Angelo, Jaye David L, De Paoli Lorenzo, Terpos Evangelos, Lonial Sagar, Boccadoro Mario, Nooka Ajay K, Dimopoulos Meletios A

机构信息

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.

出版信息

Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.

DOI:10.1038/s41408-020-0307-4
PMID:32286263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7156404/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ca/7156404/f7f40a818beb/41408_2020_307_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ca/7156404/f7f40a818beb/41408_2020_307_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ca/7156404/f7f40a818beb/41408_2020_307_Fig1_HTML.jpg

相似文献

1
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.新型药物时代携带t(14;16)的多发性骨髓瘤患者的临床特征与生存情况
Blood Cancer J. 2020 Apr 14;10(4):40. doi: 10.1038/s41408-020-0307-4.
2
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.MMSET基因中的MB4-2断点与17p缺失相结合，定义了一组预后极差的t(4;14)多发性骨髓瘤。
Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23.
3
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.t(14;16)阳性多发性骨髓瘤即使在新型药物时代，CD56表达也呈阴性且预后不良。
Blood Cancer J. 2015 Feb 27;5(2):e285. doi: 10.1038/bcj.2015.6.
4
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?易位 t(14;16)与多发性骨髓瘤：它真的是一个独立的预后因素吗？
Blood. 2011 Feb 10;117(6):2009-11. doi: 10.1182/blood-2010-07-295105. Epub 2010 Oct 20.
5
The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.t(11;14)(q13;q32)易位作为髓外浆细胞瘤骨髓瘤患者自体干细胞移植的不良预后参数。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35. doi: 10.1016/j.clml.2014.12.007. Epub 2014 Dec 12.
6
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.复杂核型和易位 t(4;14) 定义新诊断多发性骨髓瘤的高危患者：CMG2002 试验结果。
Leuk Lymphoma. 2012 May;53(5):920-7. doi: 10.3109/10428194.2011.634042. Epub 2011 Dec 13.
7
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.CD221（胰岛素样生长因子-1受体）在多发性骨髓瘤中异常表达，与疾病严重程度相关。
Haematologica. 2005 May;90(5):706-7.
8
Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.自体移植对伴有 t(11;14)的多发性骨髓瘤患者的影响：倾向评分匹配分析。
Clin Cancer Res. 2019 Nov 15;25(22):6781-6787. doi: 10.1158/1078-0432.CCR-19-0706. Epub 2019 Sep 3.
9
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.IgH 易位伴未明伙伴与多发性骨髓瘤患者的较好预后相关。
Eur J Haematol. 2020 Sep;105(3):326-334. doi: 10.1111/ejh.13440. Epub 2020 Jun 9.
10
Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.自体造血干细胞移植治疗多发性骨髓瘤患者中两种或多种细胞遗传学异常具有负预后意义。
Neoplasma. 2010;57(2):111-7. doi: 10.4149/neo_2010_02_111.

引用本文的文献

1
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group.多发性骨髓瘤风险分层的细胞遗传学结果检测与报告指南：癌症基因组学联盟浆细胞肿瘤工作组报告
Blood Cancer J. 2025 Jun 18;15(1):86. doi: 10.1038/s41408-025-01286-w.
2
A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q Abnormalities.一项关于伴有1q异常的多发性骨髓瘤患者一线治疗的单中心研究。
EJHaem. 2025 May 11;6(3):e270045. doi: 10.1002/jha2.70045. eCollection 2025 Jun.
3
A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma.
一种用于新诊断多发性骨髓瘤患者的真实世界国际分期系统（RW-ISS）。
Blood Cancer J. 2025 Apr 7;15(1):59. doi: 10.1038/s41408-025-01268-y.
4
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience.多发性骨髓瘤中的高危细胞遗传学异常：PETHEMA-GEM研究经验
Hemasphere. 2024 Dec 10;8(12):e70031. doi: 10.1002/hem3.70031. eCollection 2024 Dec.
5
[Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].19例新诊断的伴t(14;16)的多发性骨髓瘤患者的预后分析
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):944-950. doi: 10.3760/cma.j.cn121090-20240814-00303.
6
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.在 ICARIA-MM 和 IKEMA 研究中分配和验证国际分期系统的第二版。
Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w.
7
Selinexor in combination with pomalidomide and dexamethasone for the treatment of primary plasma cell leukemia with 1q21+ abnormality: A case report.塞利尼索联合泊马度胺和地塞米松治疗伴有 1q21+异常的原发性浆细胞白血病：一例报告。
Medicine (Baltimore). 2024 Nov 15;103(46):e40447. doi: 10.1097/MD.0000000000040447.
8
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.修订版国际分期系统 2 风险分层对接受自体造血干细胞移植的多发性骨髓瘤患者结局的影响。
Br J Haematol. 2024 May;204(5):1944-1952. doi: 10.1111/bjh.19384. Epub 2024 Mar 6.
9
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities.尽管存在并发染色体异常，但MAF易位仍然是一个强有力的预后因素。
Haematologica. 2024 May 1;109(5):1619-1623. doi: 10.3324/haematol.2023.284666.
10
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum.细胞遗传学异常对有症状多发性骨髓瘤的影响；来自关西骨髓瘤论坛的日本真实世界分析。
Leuk Res Rep. 2023 Nov 17;20:100395. doi: 10.1016/j.lrr.2023.100395. eCollection 2023.